New HIV drug candidate VH4524184 passes first safety check in healthy volunteers
NCT ID NCT05631704
First seen Jan 11, 2026 · Last updated May 09, 2026 · Updated 16 times
Summary
This early-stage study tested a new experimental HIV drug called VH4524184 in 84 healthy adults to see if it is safe and how the body processes it. The study also checked whether the drug affects a key liver enzyme that can change how other medicines work. Because HIV requires lifelong treatment, this is classified as disease control, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Baltimore, Maryland, 21225, United States
Conditions
Explore the condition pages connected to this study.